Angelman syndrome, a genetic disorder, leads to delayed development, speech and balance issues, intellectual disability, and occational seizures.
Individuals with this syndrome often display frequent smiling, laughter, and a happy, excitable demeanor. Developmental delays, emerging around 6 to 12 months, typically mark the initial symptoms, while seizures may commence between 2 and 3 years.
Although those with Angelman syndrome generally live a near-normal lifespan, there is no cure for the disorder.
Treatment concentrates on addressing medical, sleep, and developmental concerns to enhance the overall well-being of individuals affected by Angelman syndrome.
• Angelman syndrome, associated with chromosome 15's UBE3A gene, often arises from issues in the maternal copy.
• Typically, only the maternal UBE3A gene is active in the brain, and missing or damaged parts of this copy contribute to Angelman syndrome.
• In rare cases, inheriting two paternal gene copies can also result in the syndrome.
• Angelman syndrome is rare, and its precise genetic origins are often unknown.
• While the exact causes of these genetic changes remain uncertain, Angelman syndrome is usually not hereditary.
• However, occasional instances involve inheritance, especially with a family history, elevating the baby's risk of the syndrome.
• A conclusive diagnosis of Angelman syndrome is usually attainable through a blood test, specifically genetic testing.
• Various tests, including DNA methylation, assess parental DNA patterns to identify three of the four known genetic abnormalities causing Angelman syndrome.
• Chromosomal microarray (CMA) detects missing chromosome portions.
• In rare cases, a mutated maternal copy of the UBE3A gene can cause Angelman syndrome, identified through UBE3A gene sequencing if the DNA methylation test yields normal results.
• This comprehensive genetic testing approach enables the detection of chromosomal defects associated with Angelman syndrome, facilitating an accurate diagnosis.